ABL1 and gastrointestinal stromal tumor: Imatinib, which has multiple therapeutic targets including BCR-ABL, KIT, and the platelet-derived growth factor receptor (PDGFR), was approved for the treatment of gastrointestinal stromal tumors (GIST) (the majority of these tumors have the KIT mutation) [56].